Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison-Reference-Cited by-同舟云学术

Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison

Published:2024-05-02 Issue:1 Volume:14 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Shadman Mazyar^ORCID,Tedeschi Alessandra,Mohseninejad Leyla,Yang Keri,Lamanna Nicole,Xu Sheng,Cohen Aileen,Challagulla Swetha,Xue Mei,Williams Rhys,O’Brien Susan M.,Brown Jennifer R.^ORCID,Tam Constantine^ORCID

Funder

BeiGene funded this study.

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41408-024-01044-4.pdf

Reference13 articles.

1. Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39:3441–52.

2. Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kaźmierczak M, Lamanna N, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388:319–32.

3. Hillmen P, Eichhorst B, Brown JR, Lamanna N, O’Brien SM, Tam CS, et al. Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial. J Clin Oncol. 2023;41:1035–45.

4. Hillmen P, Brown JR, Eichhorst BF, Lamanna N, O’Brien SM, Qui L, et al. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Future Oncol. 2020;16:517–23.

5. Signorovitch JE, Sikirica V, Erder MH, Xie J, Lu M, Hodgkins PS, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15:940–7.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BTK inhibitors: past, present, and future;Trends in Pharmacological Sciences;2024-08